Albendazole Treatment for Echinococcosis in China
Author Information
Author(s): Qin Min, Yang Guobing, Yan Jun, Wang Liying, Feng Yu, Wang Dong, Wang Qian, Hou Yanyan, Zhao Jiangshan, Lei Jiaxi, Wang Zhiyi, Jiang Mingzhe, Yu Chenghang, Gavotte Laurent, Frutos Roger
Primary Institution: National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention
Hypothesis
Monitoring patient medication and its therapeutic impact will help improve medication compliance and therapeutic effect.
Conclusion
Patients demonstrated poor compliance with albendazole use, highlighting the need for improved health education and medication guidance.
Supporting Evidence
- 7.9% of patients had never taken albendazole.
- 69.2% took it irregularly, and only 22.9% took it regularly.
- Patients with higher medication adherence demonstrated better treatment outcomes.
Takeaway
This study looked at how well patients took their medicine for a disease called echinococcosis. Many didn't take it regularly, which means they didn't get better as they could have.
Methodology
Random cluster sampling was used to select 10 echinococcosis-endemic counties in China, and all albendazole-treated patients in these counties were investigated.
Potential Biases
Patients may have had recall bias during the investigation, resulting in an underestimation of medication compliance.
Limitations
35.3% of the research patients corresponding to the files were excluded from the analysis, which could have resulted in selection bias.
Participant Demographics
The study included 582 patients, with 63.2% female and 36.8% male, predominantly Tibetan and Han ethnicities, with a significant portion having no formal education.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 0.03–0.12
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website